Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer
- PMID:30422775
- DOI: 10.1148/rg.2018180060
Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer
Abstract
Lung cancer is the leading cause of cancer-related mortality in the United States, and accurate staging plays a vital role in determining prognosis and treatment. The recently revised eighth edition of the TNM staging system for lung cancer defines new T and M descriptors and updates stage groupings on the basis of substantial differences in survival. There are new T descriptors that are based on the findings at histopathologic examination, and T descriptors are reassigned on the basis of tumor size and extent. No changes were made to the N descriptors in the eighth edition of the TNM staging of lung cancer, because the four N categories that are based on the location of the diseased nodes can be used to consistently predict prognosis. The eighth edition includes a new M1b descriptor for patients with a single extrathoracic metastatic lesion in a single organ (M1b), because they have better survival and different treatment options, compared with those with multiple extrathoracic lesions (M1c). Examination with fluorine 18 fluorodeoxyglucose (FDG) PET/CT is the standard of care and is an integral part of the clinical staging of patients with lung cancer. To provide the treating physicians with accurate staging information, radiologists and nuclear medicine physicians should be aware of the updated classification system and should be cognizant of the site-specific strengths and limitations of FDG PET/CT. In this article, the eighth edition of the TNM staging system is reviewed, as well as the role of FDG PET/CT in the staging of non-small cell lung carcinoma.©RSNA, 2018.
Similar articles
- Staging Lung Cancer: Metastasis.Shroff GS, Viswanathan C, Carter BW, Benveniste MF, Truong MT, Sabloff BS.Shroff GS, et al.Radiol Clin North Am. 2018 May;56(3):411-418. doi: 10.1016/j.rcl.2018.01.009. Epub 2018 Mar 7.Radiol Clin North Am. 2018.PMID:29622076Review.
- An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.Finkle JH, Penney BC, Pu Y.Finkle JH, et al.Lung Cancer. 2018 Sep;123:136-141. doi: 10.1016/j.lungcan.2018.07.019. Epub 2018 Jul 20.Lung Cancer. 2018.PMID:30089584
- Dilemmas in Lung Cancer Staging.Vlahos I.Vlahos I.Radiol Clin North Am. 2018 May;56(3):419-435. doi: 10.1016/j.rcl.2018.01.010.Radiol Clin North Am. 2018.PMID:29622077Review.
- New revisions and current issues in the eighth edition of the TNM classification for non-small cell lung cancer.Hattori A, Takamochi K, Oh S, Suzuki K.Hattori A, et al.Jpn J Clin Oncol. 2019 Jan 1;49(1):3-11. doi: 10.1093/jjco/hyy142.Jpn J Clin Oncol. 2019.PMID:30277521Review.
- Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan.Sakai K, Kuramoto J, Kojima A, Nishimura H, Kuwabara Y, Toda M, Kobayashi Y, Kikuchi S, Hirata Y, Mikami-Saito Y, Mikami S, Kyoyama H, Moriyama G, Gemma A, Uematsu K.Sakai K, et al.Int J Clin Oncol. 2019 Dec;24(12):1549-1557. doi: 10.1007/s10147-019-01525-8. Epub 2019 Aug 26.Int J Clin Oncol. 2019.PMID:31452019
Cited by
- [Formula: see text]: deep learning-based radiomics for the time-to-event outcome prediction in lung cancer.Afshar P, Mohammadi A, Tyrrell PN, Cheung P, Sigiuk A, Plataniotis KN, Nguyen ET, Oikonomou A.Afshar P, et al.Sci Rep. 2020 Jul 23;10(1):12366. doi: 10.1038/s41598-020-69106-8.Sci Rep. 2020.PMID:32703973Free PMC article.Clinical Trial.
- Diagnostic performance of diffusion-weighted imaging versus 18F-FDG PET/CT in differentiating pulmonary lesions: an updated meta-analysis of comparative studies.Liu J, Xia X, Zou Q, Xie X, Lei Y, Wan Q, Li X.Liu J, et al.BMC Med Imaging. 2023 Mar 10;23(1):37. doi: 10.1186/s12880-023-00990-y.BMC Med Imaging. 2023.PMID:36899303Free PMC article.
- Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience.Monaco L, Gemelli M, Gotuzzo I, Bauckneht M, Crivellaro C, Genova C, Cortinovis D, Zullo L, Ammoni LC, Bernasconi DP, Rossi G, Morbelli S, Guerra L.Monaco L, et al.Cancers (Basel). 2021 Apr 1;13(7):1634. doi: 10.3390/cancers13071634.Cancers (Basel). 2021.PMID:33915801Free PMC article.
- Lung Cancer Staging: Imaging and Potential Pitfalls.Erasmus LT, Strange TA, Agrawal R, Strange CD, Ahuja J, Shroff GS, Truong MT.Erasmus LT, et al.Diagnostics (Basel). 2023 Nov 1;13(21):3359. doi: 10.3390/diagnostics13213359.Diagnostics (Basel). 2023.PMID:37958255Free PMC article.Review.
- A prospective study to compare the diagnostic accuracy of99mTc-CNDG SPECT/CT and contrast-enhanced CT in staging of non-small cell lung cancer.Wang Q, Deng Z, Lu C, Chen L, Qin J, Wang P.Wang Q, et al.J Cancer Res Clin Oncol. 2024 Sep 26;150(9):430. doi: 10.1007/s00432-024-05953-6.J Cancer Res Clin Oncol. 2024.PMID:39327339Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical